VectivBio Holding AG (VECT)
|Net Income (ttm)||-59.94M|
|Trading Day||April 9|
|Day's Range||19.32 - 37.47|
|52-Week Range||0.00 - 37.47|
VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical...
VectivBio Holding, a Swiss Phase 3 biotech developing therapies for rare gastrointestinal disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
VectivBio Holding AG has filed to go public with an IPO on the NASDAQ.
VectivBio Holding is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Our goal is to become a leading, patient-centric, fully integrated global rare disease company. Our current product pipeline is focused on rare gastrointestinal, or GI, disorders, and we intend to in-license or acquire additional transformational, differentiated rare disease assets. Our product candidate, apraglutide, i... [Read more...]
|Stock Exchange |
|Ticker Symbol |